Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.67 USD
+0.66 (16.46%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $4.99 +0.32 (6.85%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRME 4.67 +0.66(16.46%)
Will PRME be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRME
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Other News for PRME
Upper Bollinger Band Walk appears for PRME after 1.47% move
NR7 appears for PRME after 0.25% move
Prime Drink Group Granted Extension for Financial Filings
Stochastic Sell Signal appears for PRME after 4.88% move
PRME forms Bearish Engulfing on September 10